Katira Arnav, Tan Peng H
UCL Medical School, UCL Faculty of Medical Science, University College London, London WC1E 6BT, UK.
UCL Medical School, UCL Faculty of Medical Science, University College London, London WC1E 6BT, UK; Breast Unit, Whittington Health, London N19 5NF, UK.
Cancer Biol Med. 2016 Mar;13(1):101-19. doi: 10.28092/j.issn.2095-3941.2015.0092.
Adiponectin (APN), an adipokine produced by adipocytes, has been shown to have a critical role in the pathogenesis of obesity-associated malignancies. Through its receptor interactions, APN may exert its anti-carcinogenic effects including regulating cell survival, apoptosis and metastasis via a plethora of signalling pathways. Despite the strong evidence supporting this notion, some work may indicate otherwise. Our review addresses all controversies critically. On the whole, hypoadiponectinaemia is associated with increased risk of several malignancies and poor prognosis. In addition, various genetic polymorphisms may predispose individuals to increased risk of obesity-associated malignancies. We also provide an updated summary on therapeutic interventions to increase APN levels that are of key interest in this field. To date efforts to manipulate APN levels have been promising, but much work remains to be done.
脂联素（APN）是一种由脂肪细胞产生的脂肪因子，已被证明在肥胖相关恶性肿瘤的发病机制中起关键作用。通过其与受体的相互作用，脂联素可能发挥其抗癌作用，包括通过多种信号通路调节细胞存活、凋亡和转移。尽管有强有力的证据支持这一观点，但一些研究可能得出相反的结论。我们的综述批判性地探讨了所有争议。总体而言，低脂联素血症与多种恶性肿瘤的风险增加和预后不良相关。此外，各种基因多态性可能使个体易患肥胖相关恶性肿瘤的风险增加。我们还提供了关于提高脂联素水平的治疗干预措施的最新总结，这是该领域的关键研究方向。迄今为止，调节脂联素水平的努力已初见成效，但仍有许多工作要做。
Zotero 插件
